SG11201903103VA - Dual inhibitors of vista and pd-1 pathways - Google Patents
Dual inhibitors of vista and pd-1 pathwaysInfo
- Publication number
- SG11201903103VA SG11201903103VA SG11201903103VA SG11201903103VA SG11201903103VA SG 11201903103V A SG11201903103V A SG 11201903103VA SG 11201903103V A SG11201903103V A SG 11201903103VA SG 11201903103V A SG11201903103V A SG 11201903103VA SG 11201903103V A SG11201903103V A SG 11201903103VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- vista
- bangalore
- pct
- rule
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 230000009977 dual effect Effects 0.000 title abstract 3
- 230000037361 pathway Effects 0.000 title abstract 2
- -1 3-substituted 1,2,4-oxadiazole compounds Chemical class 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 abstract 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 abstract 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 abstract 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641035996 | 2016-10-20 | ||
| PCT/IB2017/056463 WO2018073754A1 (en) | 2016-10-20 | 2017-10-18 | Dual inhibitors of vista and pd-1 pathways |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903103VA true SG11201903103VA (en) | 2019-05-30 |
Family
ID=62019280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903103VA SG11201903103VA (en) | 2016-10-20 | 2017-10-18 | Dual inhibitors of vista and pd-1 pathways |
| SG10202010584XA SG10202010584XA (en) | 2016-10-20 | 2017-10-18 | Dual inhibitors of vista and pd-1 pathways |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010584XA SG10202010584XA (en) | 2016-10-20 | 2017-10-18 | Dual inhibitors of vista and pd-1 pathways |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200061030A1 (https=) |
| EP (1) | EP3529235A4 (https=) |
| JP (2) | JP7189870B2 (https=) |
| KR (1) | KR20190067235A (https=) |
| CN (1) | CN110139856A (https=) |
| AU (1) | AU2017345500B2 (https=) |
| BR (1) | BR112019007872A2 (https=) |
| CA (1) | CA3040033A1 (https=) |
| EA (1) | EA201990997A1 (https=) |
| IL (2) | IL266042A (https=) |
| MX (2) | MX2019004561A (https=) |
| MY (1) | MY205585A (https=) |
| PH (1) | PH12019500780A1 (https=) |
| SG (2) | SG11201903103VA (https=) |
| WO (1) | WO2018073754A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181052T1 (hr) | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| NZ734650A (en) | 2015-03-10 | 2023-07-28 | Aurigene Oncology Ltd | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| MY205585A (en) * | 2016-10-20 | 2024-10-28 | Aurigene Oncology Ltd | Dual inhibitors of vista and pd-1 pathways |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| IL273896B2 (en) | 2017-10-11 | 2025-08-01 | Aurigene Oncology Ltd | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| AU2018360386B2 (en) | 2017-11-03 | 2023-11-09 | Aurigene Oncology Limited | Dual inhibitors of TIM-3 and PD-1 pathways |
| CN111386128A (zh) * | 2017-11-06 | 2020-07-07 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的联合疗法 |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3737401A4 (en) | 2018-01-12 | 2021-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| WO2019175799A2 (en) * | 2018-03-14 | 2019-09-19 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| SG11202102343QA (en) * | 2018-09-11 | 2021-04-29 | Curis Inc | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| JP7623279B2 (ja) * | 2018-11-08 | 2025-01-28 | オーリジーン オンコロジー リミテッド | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP7650507B2 (ja) * | 2019-03-13 | 2025-03-25 | イーザアールエヌーエー イムノセラピーズ エンヴェー | ｍＲＮＡワクチン |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2021183685A2 (en) * | 2020-03-10 | 2021-09-16 | Shaw Gray D | Fusion molecules of psgl-1 or tsgl anionic domains to checkpoint-modulating antibodies and other antibodies |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| CN115666576B (zh) * | 2020-05-15 | 2025-06-13 | 上海科技大学 | 一种治疗和/或预防冠状病毒引发的疾病的化合物及其应用 |
| CN113679724B (zh) * | 2020-05-18 | 2023-04-07 | 中国科学院微生物研究所 | 一种流感病毒小分子抑制剂 |
| CN113797313A (zh) * | 2020-06-11 | 2021-12-17 | 华北制药集团新药研究开发有限责任公司 | 卡非佐米作为冠状病毒广谱抑制剂的新用途 |
| US11833209B2 (en) | 2020-09-11 | 2023-12-05 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof |
| EP4337223A1 (en) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023219948A1 (en) * | 2022-05-08 | 2023-11-16 | The Regents Of The University Of Colorado, A Body Corporate | Therapeutic biomaterial that attenuates the foreign body response |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| CN118516308B (zh) * | 2024-07-22 | 2024-10-22 | 深圳市中佳生物医疗科技有限公司 | 免疫调节剂在制备增强nk细胞毒性作用的产品中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181052T1 (hr) * | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| NZ734650A (en) * | 2015-03-10 | 2023-07-28 | Aurigene Oncology Ltd | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| EP3267985A4 (en) * | 2015-03-10 | 2018-07-25 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| WO2018047143A1 (en) * | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
| MY205585A (en) * | 2016-10-20 | 2024-10-28 | Aurigene Oncology Ltd | Dual inhibitors of vista and pd-1 pathways |
-
2017
- 2017-10-18 MY MYPI2019002080A patent/MY205585A/en unknown
- 2017-10-18 SG SG11201903103VA patent/SG11201903103VA/en unknown
- 2017-10-18 JP JP2019520894A patent/JP7189870B2/ja active Active
- 2017-10-18 US US16/343,681 patent/US20200061030A1/en not_active Abandoned
- 2017-10-18 CN CN201780078731.XA patent/CN110139856A/zh active Pending
- 2017-10-18 AU AU2017345500A patent/AU2017345500B2/en active Active
- 2017-10-18 CA CA3040033A patent/CA3040033A1/en active Pending
- 2017-10-18 SG SG10202010584XA patent/SG10202010584XA/en unknown
- 2017-10-18 EP EP17862427.6A patent/EP3529235A4/en not_active Withdrawn
- 2017-10-18 EA EA201990997A patent/EA201990997A1/ru unknown
- 2017-10-18 KR KR1020197014205A patent/KR20190067235A/ko not_active Ceased
- 2017-10-18 MX MX2019004561A patent/MX2019004561A/es unknown
- 2017-10-18 BR BR112019007872A patent/BR112019007872A2/pt not_active Application Discontinuation
- 2017-10-18 WO PCT/IB2017/056463 patent/WO2018073754A1/en not_active Ceased
-
2019
- 2019-04-11 PH PH12019500780A patent/PH12019500780A1/en unknown
- 2019-04-15 IL IL266042A patent/IL266042A/en unknown
- 2019-04-17 MX MX2023007973A patent/MX2023007973A/es unknown
-
2021
- 2021-10-24 IL IL287518A patent/IL287518A/en unknown
-
2022
- 2022-09-16 JP JP2022148392A patent/JP2022191239A/ja active Pending
-
2024
- 2024-12-12 US US18/979,176 patent/US20250195478A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ753204A (en) | 2023-09-29 |
| SG10202010584XA (en) | 2020-12-30 |
| JP7189870B2 (ja) | 2022-12-14 |
| JP2019532083A (ja) | 2019-11-07 |
| IL266042A (en) | 2019-06-30 |
| PH12019500780A1 (en) | 2019-08-05 |
| WO2018073754A1 (en) | 2018-04-26 |
| US20250195478A1 (en) | 2025-06-19 |
| MX2019004561A (es) | 2019-08-05 |
| MY205585A (en) | 2024-10-28 |
| EA201990997A1 (ru) | 2019-08-30 |
| CN110139856A (zh) | 2019-08-16 |
| IL287518A (en) | 2021-12-01 |
| EP3529235A1 (en) | 2019-08-28 |
| US20200061030A1 (en) | 2020-02-27 |
| MX2023007973A (es) | 2023-07-18 |
| CA3040033A1 (en) | 2018-04-26 |
| JP2022191239A (ja) | 2022-12-27 |
| KR20190067235A (ko) | 2019-06-14 |
| BR112019007872A2 (pt) | 2019-07-02 |
| EP3529235A4 (en) | 2020-07-08 |
| AU2017345500A1 (en) | 2019-05-23 |
| AU2017345500B2 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903103VA (en) | Dual inhibitors of vista and pd-1 pathways | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201906249PA (en) | Methods, compositions, and kits for treatment of cancer | |
| SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
| SG11201809560QA (en) | Enhancer of zeste homolog 2 inhibitors | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch |